申请人:FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
公开号:US10865194B2
公开(公告)日:2020-12-15
Pharmaceutical compounds are disclosed having a bicyclic-sulphonamide structure of Formula 1:
wherein R1 represents an unsubstituted or a substituted heteroaryl ring; R2, R3, R4, and R5 are independently selected from hydrogen, alkyl, hydroxyalkyl, and alkyl-O-alkyl, provided that either R2 and R3, or R4 and R5 are linked or taken together to form a bridge between the carbon atoms to which R2 and R3, or R4 and R5 respectively are directly linked, whereby the N-containing ring in Formula 1 is an azabicyclo moiety. The compounds and compositions including the compounds may be used in therapy as brain-cell-death protectants, for example, in the treatment of chronic neurodegenerative diseases. The compounds are active as inhibitors of N-acylethanolamine-hydrolysing acid amidase (NAAA) and may be used for the therapeutic treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamides, particularly palmitoylethanolamide (PEA).
本发明公开了具有式 1 双环磺酰胺结构的药物化合物:
其中R1代表未取代的或取代的杂芳基环;R2、R3、R4和R5独立地选自氢、烷基、羟烷基和烷基-O-烷基,条件是R2和R3或R4和R5相连或一起在R2和R3或R4和R5分别直接相连的碳原子之间形成桥,其中式1中的含N环是氮杂双环分子。这些化合物和包括这些化合物的组合物可作为脑细胞死亡保护剂用于治疗,例如用于治疗慢性神经退行性疾病。这些化合物作为 N-乙酰乙醇胺-水解酸酰胺酶(NAAA)的抑制剂具有活性,可用于治疗和预防疼痛、炎症性疾病以及其他受益于脂肪酸乙醇酰胺(尤其是棕榈酰乙醇酰胺(PEA))调节的疾病。